DK2285387T3 - Ernæring til forebyggelse af infektioner - Google Patents
Ernæring til forebyggelse af infektioner Download PDFInfo
- Publication number
- DK2285387T3 DK2285387T3 DK09762710.3T DK09762710T DK2285387T3 DK 2285387 T3 DK2285387 T3 DK 2285387T3 DK 09762710 T DK09762710 T DK 09762710T DK 2285387 T3 DK2285387 T3 DK 2285387T3
- Authority
- DK
- Denmark
- Prior art keywords
- oligosaccharides
- composition
- bifidobacteria
- present
- preparation
- Prior art date
Links
- 235000016709 nutrition Nutrition 0.000 title claims description 52
- 208000015181 infectious disease Diseases 0.000 title claims description 21
- 230000035764 nutrition Effects 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 claims description 125
- 241000186000 Bifidobacterium Species 0.000 claims description 87
- 238000002360 preparation method Methods 0.000 claims description 82
- 229920001542 oligosaccharide Polymers 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 63
- 108010046377 Whey Proteins Proteins 0.000 claims description 61
- 102000007544 Whey Proteins Human genes 0.000 claims description 60
- 239000000758 substrate Substances 0.000 claims description 58
- 235000021140 nondigestible carbohydrates Nutrition 0.000 claims description 38
- 150000002482 oligosaccharides Chemical class 0.000 claims description 35
- 235000021119 whey protein Nutrition 0.000 claims description 35
- 230000007358 intestinal barrier function Effects 0.000 claims description 32
- 230000008569 process Effects 0.000 claims description 30
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 26
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 26
- 239000005862 Whey Substances 0.000 claims description 26
- 239000008101 lactose Substances 0.000 claims description 26
- 235000013336 milk Nutrition 0.000 claims description 24
- 239000008267 milk Substances 0.000 claims description 24
- 210000004080 milk Anatomy 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 22
- 210000005027 intestinal barrier Anatomy 0.000 claims description 22
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 20
- 206010070545 Bacterial translocation Diseases 0.000 claims description 17
- 230000007375 bacterial translocation Effects 0.000 claims description 17
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 15
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 15
- 239000003531 protein hydrolysate Substances 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 108010076119 Caseins Proteins 0.000 claims description 13
- 102000011632 Caseins Human genes 0.000 claims description 13
- 102000014171 Milk Proteins Human genes 0.000 claims description 13
- 108010011756 Milk Proteins Proteins 0.000 claims description 13
- 239000005018 casein Substances 0.000 claims description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 13
- 235000021240 caseins Nutrition 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 12
- 235000021239 milk protein Nutrition 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 11
- 230000000415 inactivating effect Effects 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000035800 maturation Effects 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical group OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- 230000035699 permeability Effects 0.000 claims description 7
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 235000021125 infant nutrition Nutrition 0.000 claims description 4
- 150000003272 mannan oligosaccharides Chemical class 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 241000831652 Salinivibrio sharmensis Species 0.000 claims description 2
- 230000003292 diminished effect Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 29
- 238000011534 incubation Methods 0.000 description 27
- 241000894006 Bacteria Species 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 150000001720 carbohydrates Chemical class 0.000 description 21
- 235000014633 carbohydrates Nutrition 0.000 description 20
- 241000186012 Bifidobacterium breve Species 0.000 description 16
- 235000013350 formula milk Nutrition 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 230000002779 inactivation Effects 0.000 description 11
- 108010009736 Protein Hydrolysates Proteins 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- -1 galacturonic acid oligosaccharide Chemical class 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 229920001202 Inulin Polymers 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 108010079058 casein hydrolysate Proteins 0.000 description 8
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 8
- 229940029339 inulin Drugs 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 150000002772 monosaccharides Chemical group 0.000 description 7
- 239000012465 retentate Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 230000003870 intestinal permeability Effects 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 235000021056 liquid food Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000001814 pectin Substances 0.000 description 5
- 229920001277 pectin Polymers 0.000 description 5
- 235000010987 pectin Nutrition 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 235000019871 vegetable fat Nutrition 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000001010 compromised effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 3
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000021536 Sugar beet Nutrition 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- AJNVQOSZGJRYEI-UHFFFAOYSA-N digallium;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Ga+3].[Ga+3] AJNVQOSZGJRYEI-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical class [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186014 Bifidobacterium angulatum Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241001312346 Bifidobacterium gallicum Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 241001034431 Bifidobacterium thermacidophilum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000005905 Hydrolysed protein Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241001414291 Stomatobaculum longum Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000020218 follow-on milk formula Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 1
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000006198 methoxylation reaction Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000020612 ready-to-feed formula Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000020161 semi-skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pediatric Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Fremgangsmåde til fremstilling af et præparat, omfattende de følgende trin: a: inkubere et vandigt substrat med bifidobakterier, hvor substratet omfatter mindst én udvalgt fra gruppen bestående af mælk, mælkeprotein, valle, valleprotein, valleproteinhydrolysat, kaseinhydrolysat, og laktose for at opnå en inkuberet blanding; b: inaktivere bifidobakterierne ved at opvarme den inkuberede blanding og/eller fjerne bifidobakterieceller fra den inkuberede blanding ved hjælp af centrifugering og/eller filtrering; c: kombinere en sammensætning omfattende den blanding, som opnås i trin a eller opnås i trin b, fortrinsvis opnået i trin b med mindst to forskellige ikke-fordøjelige kulhydrater, hvor fortrinsvis mindst én, fortrinsvis to, er udvalgt fra gruppen bestående af fructo-oligosaccharider, galacto-oligosaccharider, glu-co-oligosaccharider, arabino-oligosaccharider, mannan-oligosaccharider, xylo-oligosaccharider, fuco-oligosaccharider, arabinogalacto- oligosaccharider, glucomanno-oligosaccharider, galactomanno-oligosaccharider, raffinose, lactosucrose, sialinsyre omfattende oligosaccha-rider og uronsyre-oligosaccharider.
2. Fremgangsmåde ifølge krav 1, hvor bifidobakterierne tilhører arten B. breve, fortrinsvis stammen B. breve CNCM 1-2219.
3. Fremgangsmåde ifølge et af de foregående krav, yderligere omfattende følgende trin: d: inkubere et substrat med Streptococcus thermophilus, fortrinsvis stammen S. thermophilus CNCM 1-1620 eller CNCM 1-1470, hvor substratet er mindst én udvalgt fra gruppen bestående af mælk, mælkeprotein, valle, valleprotein, valleproteinhydrolysat, kasein, kaseinhydrolysat, og laktose for at opnå en inkuberet blanding, og e: inaktivere S. thermophilus ved at opvarme den inkuberede blanding af trin d og/eller fjerne S. thermophilus-celler fra den inkuberede blanding af trin e ved hjælp af centrifugering og/eller filtrering; f: kombinere den inkuberede blanding opnået i trin d eller e, fortrinsvis trin d, med den inkuberede blanding opnået i trin a, b eller c, fortrinsvis i trin a.
4. Fremgangsmåde ifølge et af de foregående krav, hvor de ikke-fordøjelige kulhydrater er mindst én, fortrinsvis mindst to, udvalgt fra gruppen bestående af galacto-oligosaccharider og fructo-oligosaccharider.
5. Fremgangsmåde ifølge et af de foregående krav, hvor fremstillingen efter trin b omfatter mindre end 103 cfu levende bifidobakterier per g tørvægt af præparatet.
6. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, yderligere omfattende et tørringstrin.
7. Fremgangsmåde ifølge et af de foregående krav, hvor der i trin c kun tilsættes én ikke-fordøjelig kulhydrat, hvor det ikke-fordøjelige kulhydrat er fruc-to-oligosaccharid.
8. Præparat, der kan opnås ved hjælp af fremgangsmåden ifølge et hvilket som helst af de foregående krav.
9. Ernæringssammensætning omfattende eller bestående af præparatet ifølge krav 8.
10. Sammensætning ifølge krav 9, omfattende 0,5 til 10 g ikke-fordøjeligt kulhydrat per 100 g tørvægt af sammensætningen.
11. Spædbørnsernæring omfattende, på basis af tørvægt af småbørnsernæ-ringen a) fra 0,5 til 10 vægt% af summen af galacto-oligosaccharider og fructo-oligosaccharider, og b) fra 5 til 99,5 vægt% af præparatet opnået efter trin b ifølge et af krav 1 til krav 5, hvor bifidobakterierne i trin a tilhører arten B. breve c) og eventuelt 2 til 94,5 vægt% af præparatet opnået i trin e ifølge et af kravene 3 til 6.
12. Sammensætning ifølge et af kravene 9 til 11 til anvendelse til at tilvejebringe ernæring til et spædbarn.
13. Sammensætning ifølge et af kravene 9 til 12 til anvendelse ved behandling og/eller forebyggelse af en sygdom.
14. Sammensætning eller præparat ifølge et af kravene 8 til 13 til anvendelse ved behandling og/eller forebyggelse af infektioner og/eller diarré.
15. Sammensætning eller præparat ifølge et af kravene 8 til 14 til anvendelse ved behandling og/eller forebyggelse af bakterietranslokation.
16. Sammensætning eller præparat ifølge et af kravene 8 til 14 til anvendelse ved forbedring af intestinal barrierefunktion, stigning i intestinal barrieremodning og/eller formindsket intestinal barrierepermeabilitet.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2008/050375 WO2009151315A1 (en) | 2008-06-13 | 2008-06-13 | Nutritional composition for infants delivered via caesarean section |
| EP08168054 | 2008-10-31 | ||
| PCT/NL2009/050330 WO2009151329A1 (en) | 2008-06-13 | 2009-06-12 | Nutrition for prevention of infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2285387T3 true DK2285387T3 (da) | 2016-01-25 |
Family
ID=40935729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09762710.3T DK2285387T3 (da) | 2008-06-13 | 2009-06-12 | Ernæring til forebyggelse af infektioner |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20110182934A1 (da) |
| EP (4) | EP2285387B1 (da) |
| CN (3) | CN102123715B (da) |
| AR (3) | AR072141A1 (da) |
| BR (1) | BRPI0915149B1 (da) |
| DK (1) | DK2285387T3 (da) |
| ES (2) | ES2558960T3 (da) |
| HU (1) | HUE028390T2 (da) |
| PL (2) | PL2285387T3 (da) |
| PT (1) | PT2285387E (da) |
| RU (2) | RU2498605C2 (da) |
| SI (1) | SI2285387T1 (da) |
| WO (3) | WO2009151329A1 (da) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101969966B (zh) | 2007-12-07 | 2013-05-08 | 努特里希亚公司 | 用于尘螨变态反应的双歧杆菌 |
| AR072141A1 (es) * | 2008-06-13 | 2010-08-11 | Nutricia Nv | Composicion nutricional para lactantes nacidos por cesarea |
| MX338680B (es) | 2009-05-11 | 2016-04-27 | Nestec Sa | Bifidobacterium longum ncc2705 (cncm i-2618) y padecimientos inmunes. |
| EP2552464B1 (en) * | 2010-03-30 | 2018-02-28 | Assistance Publique - Hôpitaux de Paris | Use of bifidobacteria for preventing allergy in breastfed infants |
| WO2011148221A1 (en) * | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Lactic acid bacteria for maturation of the enteric nervous system in infants |
| EP3097791B1 (en) * | 2010-06-04 | 2018-05-16 | N.V. Nutricia | Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
| WO2011150949A1 (en) * | 2010-06-04 | 2011-12-08 | N.V. Nutricia | Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
| KR101757504B1 (ko) * | 2010-06-28 | 2017-07-12 | 가부시키가이샤 야쿠르트 혼샤 | 경구용 피부 성상 개선제 |
| WO2012057636A1 (en) * | 2010-10-27 | 2012-05-03 | Fonterra Corporate Research And Development Limited | Modulation of th1 and th2 immune response by lactic acid whey |
| EP2449891A1 (en) * | 2010-11-05 | 2012-05-09 | Nestec S.A. | Drinking yoghurt preparations containing non-replicating probiotic micro-organisms |
| US20130287874A1 (en) * | 2010-11-11 | 2013-10-31 | Nestec S.A. | Spoonable yogurt preparations containing non-replicating probiotic micro-organisms |
| CN103209596A (zh) * | 2010-11-11 | 2013-07-17 | 雀巢产品技术援助有限公司 | 含有益生微生物的冷冻糖食 |
| EP2465508A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
| CN107890097A (zh) * | 2010-12-06 | 2018-04-10 | N·V·努特里奇亚 | 发酵的婴儿配方物 |
| WO2012078030A1 (en) * | 2010-12-06 | 2012-06-14 | N.V. Nutricia | Fermented infant formula |
| EP2520181A1 (en) * | 2011-05-02 | 2012-11-07 | N.V. Nutricia | Fermented infant formula |
| WO2012078032A1 (en) | 2010-12-10 | 2012-06-14 | N.V. Nutricia | Early stimulation of taste and/or flavour acceptance |
| SG10201707519PA (en) * | 2010-12-31 | 2017-10-30 | Abbott Lab | Neutral human milk oligosaccharides to promote growth of beneficial bacteria |
| DK2481299T3 (da) * | 2011-01-31 | 2017-02-06 | Dr Fischer Gesundheitsprodukte Gmbh | Bifidobacterium bifidum stammer til brug i gastrointestinale sygdomme |
| WO2013016111A1 (en) | 2011-07-22 | 2013-01-31 | Abbott Laboratories | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| WO2013053073A1 (zh) * | 2011-10-10 | 2013-04-18 | Huang Daiyong | 一种基于甘露寡糖的胃肠道健康因子组合物 |
| WO2013187755A1 (en) * | 2012-06-14 | 2013-12-19 | N.V. Nutricia | Fermented infant formula with non digestible oligosaccharides |
| PL2914136T3 (pl) * | 2012-11-02 | 2021-11-29 | N.V. Nutricia | Połączenie synbiotyków do poprawy czynności mózgu |
| IL240830B (en) * | 2013-02-28 | 2022-08-01 | Teewinot Tech Limited | Processes for chemical engineering and the device for the synthesis of compounds |
| US20140271978A1 (en) * | 2013-03-15 | 2014-09-18 | Mead Johnson Nutrition Company | Low-buffer nutritional compositions and uses thereof |
| US9352020B2 (en) * | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
| US20160089400A1 (en) * | 2013-04-08 | 2016-03-31 | N.V. Nutricia | Fermented nutritional composition with thiol protease inhibitor |
| WO2014200334A1 (en) * | 2013-06-14 | 2014-12-18 | N.V. Nutricia | Synbiotic composition for treatment of infections in allergic patients |
| CN104413334A (zh) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | 可食用组合物及其制备方法和用途 |
| EP2857410A1 (en) | 2013-10-04 | 2015-04-08 | Jennewein Biotechnologie GmbH | Process for purification of 2´-fucosyllactose using simulated moving bed chromatography |
| WO2015071389A1 (en) | 2013-11-15 | 2015-05-21 | Nestec S.A. | Compositions for use in the prevention or treatment of urt infections in infants or young children at risk |
| CN105899089A (zh) * | 2013-12-19 | 2016-08-24 | 雀巢产品技术援助有限公司 | 用于减少婴儿代谢应激、降低肠道通透性和接近母乳喂养婴儿的生长速度的营养组合物 |
| WO2016030828A1 (en) | 2014-08-25 | 2016-03-03 | Full Spectrum Laboratories Limited | Apparatus and methods for the simultaneous production of cannabinoid compounds |
| WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
| WO2017043962A1 (en) * | 2015-09-11 | 2017-03-16 | N.V. Nutricia | Method for stimulating microbiota health after non-natural birth |
| EP3150257A1 (en) * | 2015-09-30 | 2017-04-05 | Buga, Doris | A method for producing a composition for strengthening the immune system |
| CN105341938B (zh) * | 2015-10-10 | 2018-06-26 | 北京康比特体育科技股份有限公司 | 一种降低大强度运动后呼吸道感染率的保健食品 |
| WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
| BR112018013501B1 (pt) * | 2015-12-29 | 2022-12-20 | N.V. Nutricia | Uso de um ingrediente fermentado e oligossacarídeo não digerível |
| CN108697141A (zh) * | 2015-12-29 | 2018-10-23 | N·V·努特里奇亚 | 含有不可消化寡糖和非复制型产乳酸细菌的营养配方物 |
| US20190159500A1 (en) | 2016-05-10 | 2019-05-30 | N.V. Nutricia | Fermented infant formula |
| PT3454674T (pt) | 2016-05-10 | 2021-03-09 | Nutricia Nv | Métodos de uso da fórmula infantil fermentada |
| MY186302A (en) * | 2016-09-30 | 2021-07-07 | A2 Milk Co Ltd | Beta-caseins and gut microbiota |
| CN110573164B (zh) * | 2017-03-08 | 2023-09-29 | N·V·努特里奇亚 | 用于减轻鼻上皮炎症的含有不可消化的低聚糖的组合物 |
| US20200305488A1 (en) * | 2017-07-07 | 2020-10-01 | Societe Des Produitis Nestle S.A. | Human milk fortifier |
| CN107397230A (zh) * | 2017-08-21 | 2017-11-28 | 杭州特悘衡康生物科技有限公司 | 营养组合物、促进手术后肌肉恢复和蛋白质合成的配方食品及其应用 |
| US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
| WO2019115382A1 (en) * | 2017-12-11 | 2019-06-20 | N.V. Nutricia | Composition for use for treating delayed colonization by bifidobacterium after birth |
| EP3749328A1 (en) | 2018-02-09 | 2020-12-16 | N.V. Nutricia | Fermented formula with non-digestible oligosaccharides |
| EP3749329A1 (en) | 2018-02-09 | 2020-12-16 | N.V. Nutricia | Fermented formula with non-digestible oligosaccharides |
| US20210346434A1 (en) | 2019-01-16 | 2021-11-11 | N.V. Nutricia | Fermented formula with non-digestible oligosaccharides for use in rotavirus induced infection |
| WO2020161113A1 (en) | 2019-02-04 | 2020-08-13 | N.V. Nutricia | Fermented formula with non digestible oligosaccharides for sleep improvement |
| WO2020229689A1 (en) | 2019-05-15 | 2020-11-19 | N.V. Nutricia | Fermented formula for improving intestinal development |
| US20220248739A1 (en) * | 2019-05-29 | 2022-08-11 | N.V. Nutricia | Non-digestible oligosaccharides for decreased colonic protein fermentation |
| DK3979827T3 (da) | 2019-06-04 | 2023-09-25 | Nutricia Nv | Næringssammensætning omfattende 2'fucosyllactose og 3'galactosyllactose |
| US20220079962A1 (en) | 2019-06-04 | 2022-03-17 | N.V. Nutricia | Nutritional composition comprising 2'fucosyllactose and dietary butyrate |
| CN110839698A (zh) * | 2019-11-29 | 2020-02-28 | 内蒙古伊利实业集团股份有限公司 | 一种组合物及其食品用途 |
| GB2608587A (en) * | 2021-06-25 | 2023-01-11 | Mjn Us Holdings Llc | Use of extensively hydrolysed protein |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110476A (en) | 1977-01-10 | 1978-08-29 | Johnson/Rhodes Cultured Foods, Inc. | Preparation of liquid and frozen yogurt products |
| RU2031586C1 (ru) * | 1993-02-05 | 1995-03-27 | Тамара Георгиевна Извекова | Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения |
| FR2723963B1 (fr) * | 1994-08-31 | 1997-01-17 | Gervais Danone Co | Preparation de produits fermentes par streptococcus thermophilus, enrichis en galacto-oligosaccharides et en beta-galactosidase |
| EP1020123A1 (en) | 1999-01-18 | 2000-07-19 | Sitia-Yomo S.p.A. | Beverages containing live lactic bacteria |
| FR2795917B1 (fr) | 1999-07-06 | 2001-08-31 | Gervais Danone Sa | Procede de preparation d'un produit lacte immunostimulant et ses applications |
| EP1062873A1 (en) * | 1999-12-13 | 2000-12-27 | N.V. Nutricia | Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate |
| IL151280A0 (en) | 2000-03-01 | 2003-04-10 | Nestle Sa | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response |
| EP1145643A1 (en) | 2000-04-10 | 2001-10-17 | Phillip Connolly | Improved milk protein concentrate |
| US7431939B1 (en) | 2000-09-28 | 2008-10-07 | Mississippi State University | Inhibition of systemic infections in humans and vertebrates by dietary fibers |
| EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
| RU2220579C1 (ru) * | 2002-07-31 | 2004-01-10 | Зенович Сергей Михайлович | Пищевой преимущественно кисломолочный продукт и закваска для его получения (варианты) |
| WO2004032639A1 (en) * | 2002-10-11 | 2004-04-22 | Wyeth | Nutritional formulations containing synbiotic substances |
| GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
| AU2003303894A1 (en) * | 2003-01-30 | 2004-08-30 | The Regents Of The University Of California | Inactivated probiotic bacteria and methods of use thereof |
| FR2853908B1 (fr) * | 2003-04-16 | 2005-06-03 | Gervais Danone Sa | Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant |
| FR2857026B1 (fr) | 2003-04-16 | 2012-11-16 | Gervais Danone Sa | Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant |
| US8394370B2 (en) * | 2003-06-23 | 2013-03-12 | Nestec S.A. | Nutritional formula for optimal gut barrier function |
| EP2033529B1 (en) * | 2003-10-24 | 2019-12-11 | N.V. Nutricia | Synbiotic composition for infants |
| EP2123282A3 (en) | 2003-10-24 | 2010-01-20 | N.V. Nutricia | Immunemodulating oligosaccharides |
| EP1597978A1 (en) * | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
| US8252769B2 (en) | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
| US7862808B2 (en) * | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
| US20100022451A1 (en) | 2004-12-27 | 2010-01-28 | Nestec S.A. | Use of infant formula with reduced protein content |
| ES2781328T3 (es) * | 2005-02-21 | 2020-09-01 | Nestle Sa | Mezcla de oligosacáridos |
| PL2805625T5 (pl) * | 2005-02-28 | 2023-03-13 | N.V. Nutricia | Kompozycja odżywcza z prebiotykami i probiotykami |
| US7303745B2 (en) * | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| EP1776877A1 (en) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| US20090156550A1 (en) | 2005-12-06 | 2009-06-18 | Potappel-Van T Land Belinda | Composition containing oligosaccharides for the treatment/prevention of infections |
| WO2007081981A2 (en) | 2006-01-11 | 2007-07-19 | Attune Foods | Probiotic food, process for its preparation and dietary regimen |
| WO2008153377A1 (en) * | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
| AR072141A1 (es) | 2008-06-13 | 2010-08-11 | Nutricia Nv | Composicion nutricional para lactantes nacidos por cesarea |
| WO2010008272A1 (en) | 2008-07-15 | 2010-01-21 | N.V. Nutricia | Treatment of gut motility disorders |
| WO2010070613A2 (en) | 2008-12-18 | 2010-06-24 | University College London | Baby feeding formula and system |
| CN107890097A (zh) | 2010-12-06 | 2018-04-10 | N·V·努特里奇亚 | 发酵的婴儿配方物 |
| WO2012078030A1 (en) | 2010-12-06 | 2012-06-14 | N.V. Nutricia | Fermented infant formula |
| EP2520181A1 (en) | 2011-05-02 | 2012-11-07 | N.V. Nutricia | Fermented infant formula |
| MX2011007872A (es) | 2011-07-26 | 2013-01-29 | Nucitec Sa De Cv | Composicion nutrimental para niños que presentan reflujo, colico y/o estreñimiento. |
-
2009
- 2009-06-12 AR ARP090102156A patent/AR072141A1/es unknown
- 2009-06-12 SI SI200931354T patent/SI2285387T1/sl unknown
- 2009-06-12 RU RU2011100829/10A patent/RU2498605C2/ru active
- 2009-06-12 ES ES09762710.3T patent/ES2558960T3/es active Active
- 2009-06-12 US US12/997,527 patent/US20110182934A1/en not_active Abandoned
- 2009-06-12 CN CN200980131512.9A patent/CN102123715B/zh active Active
- 2009-06-12 EP EP09762710.3A patent/EP2285387B1/en active Active
- 2009-06-12 CN CN200980131387.1A patent/CN102118976B/zh active Active
- 2009-06-12 PL PL09762710T patent/PL2285387T3/pl unknown
- 2009-06-12 WO PCT/NL2009/050330 patent/WO2009151329A1/en active Application Filing
- 2009-06-12 EP EP09762712A patent/EP2293803A1/en not_active Ceased
- 2009-06-12 PL PL09762711T patent/PL2293677T3/pl unknown
- 2009-06-12 RU RU2011100828/15A patent/RU2543634C2/ru active
- 2009-06-12 PT PT97627103T patent/PT2285387E/pt unknown
- 2009-06-12 ES ES09762711.1T patent/ES2656776T3/es active Active
- 2009-06-12 WO PCT/NL2009/050333 patent/WO2009151331A1/en active Application Filing
- 2009-06-12 AR ARP090102151A patent/AR078014A1/es unknown
- 2009-06-12 CN CN2009801222425A patent/CN102065867A/zh active Pending
- 2009-06-12 DK DK09762710.3T patent/DK2285387T3/da active
- 2009-06-12 US US12/997,541 patent/US20110097437A1/en not_active Abandoned
- 2009-06-12 BR BRPI0915149-4A patent/BRPI0915149B1/pt active IP Right Grant
- 2009-06-12 EP EP17205129.4A patent/EP3326633A1/en not_active Withdrawn
- 2009-06-12 EP EP09762711.1A patent/EP2293677B1/en active Active
- 2009-06-12 HU HUE09762710A patent/HUE028390T2/en unknown
- 2009-06-12 AR ARP090102157A patent/AR072142A1/es unknown
- 2009-06-12 US US12/997,537 patent/US20110117077A1/en not_active Abandoned
- 2009-06-12 WO PCT/NL2009/050332 patent/WO2009151330A1/en active Application Filing
-
2016
- 2016-09-28 US US15/278,475 patent/US20170173104A1/en not_active Abandoned
-
2017
- 2017-01-13 US US15/406,361 patent/US10124016B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2285387T3 (da) | Ernæring til forebyggelse af infektioner | |
| US10092606B2 (en) | Synbiotic mixture | |
| US8591919B2 (en) | Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta -1,4/1,6 linkages | |
| WO2009151315A1 (en) | Nutritional composition for infants delivered via caesarean section | |
| US20110150851A1 (en) | Nutritional composition for infants delivered via caesarean section | |
| CN113194746A (zh) | 用以改善胃肠屏障的包含人乳低聚糖的组合的营养组合物 | |
| RU2724536C2 (ru) | Ферментированная молочная смесь с неперевариваемыми олигосахаридами | |
| WO2017114901A1 (en) | Nutritional formula with non-digestible oligosaccharides and non-replicating lactic acid producing bacteria | |
| US20160206658A1 (en) | Nutrition for prevention of infections |